4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting

4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, M.D., in an oral presentation titled, "Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration," at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting held in Stockholm, Sweden.